Thoratec Corporation, a Pleasanton-based developer of mechanical circulatory support therapies to save, support and restore failing hearts, will be participating in the Canaccord Genuity 34th Annual Growth Conference today.
The conference, to be held at the Intercontinental Hotel in Boston, is sponsored by Canaccord Genuity, a Canadian banking and financial services company that specialises in wealth management and brokerage in capital markets.
Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on Thoratec starting at 11 a.m. Pacific time.
A webcast of the presentation will be available at http://wsw.com/webcast/canaccord14/THOR, or on the company's website at http://www.thoratec.com/
Thoratec is a leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate IIŪ and HeartMate III(TM) LVAS (Left Ventricular Assist Systems) and ThoratecŪ VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure.
Thoratec also manufactures and distributes the CentriMagŪ and PediMagŪ/PediVASŪ, and HeartMate PHP(TM) product lines.
Thoratec's headquarters are on Johnson Drive in Pleasanton.
For more information, visit the company's website at http://www.thoratec.com/